linjc16/ctgov huggingface dataset:
A Survey of the Indications for Esophagogastroduodenoscopy (EGD) in Children's Hospital of Fudan University

Study Overview
=================
Brief Summary
-----------------
Esophagogastroduodenoscopy (EGD) become more and more common in diagnosing gastroenterology diseases. The investigators want to find which symptoms can support for positive endoscopic findings.

Detailed Description
-----------------
Esophagogastroduodenoscopy (EGD) become more and more common in diagnosing gastroenterology diseases. And there are indications for EGD. Here, investigators want to find which symptoms can strongly support for positive endoscopy findings. So, investigators design the study to record the symptoms in detail and diagnosis, and then analysis symptoms and the rate of endoscopic findings.

Official Title
-----------------
A Survey of the Indications for Esophagogastroduodenoscopy (EGD) in Children's Hospital of Fudan University

Conditions
-----------------
Digestive System Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All of the patients need esophagogastroduodenoscopic procedures Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| children<br>Investigators give observation to the patients who need esophagogastroduodenoscopic procedures. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaires about the indications for esophagogastroduodenoscopic procedures were collected | The content of questionnaire include the symptoms which prompt for the esophagogastroduodenoscopic procedure, and the diagnosis. Then investigators will analysis the relationship between symptom and diagnosis. | May, 2016-August, 2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophagogastroduodenoscopy, paediatric
Evaluation of Video Laryngoscopes in Difficult Airway

Study Overview
=================
Brief Summary
-----------------
In this multicenter study the investigators are going to evaluate the use of six different videolaryngoscopes in patients undergoing elective surgery requiring general anesthesia with intubation. The investigators are hypothesizing that these six videolaryngoscopes will succeed for intubation at first attempt in at least 90% of all cases using a difficult airway simulation with extrication collars. As gold standard, a standard Macintosh blade is being used. The study consists of 6 arms. Each arm includes 120 patients, sums up to a total of 720 patients.

Official Title
-----------------
Multicenter Study Evaluating Video Laryngoscopes: The Swiss Video-Intubation Trial (SWIVIT I)

Conditions
-----------------
Intubation; Difficult

Intervention / Treatment
-----------------
* Procedure: Intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective surgery with general anesthesia requiring intubation >18years old ASA I-III Exclusion Criteria: known or presumed difficult airway risk of pulmonary aspiration refusing to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GlideScope<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|
| Experimental: Airtraq<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|
| Experimental: McGrath MAC<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|
| Experimental: King Vision<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|
| Experimental: A.P. Advance<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|
| Experimental: C-MAC<br>intubation | Procedure: Intubation<br>* Intubation with one of the six videolaryngoscopes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| First attempt intubation success rate |  | within 180 seconds | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| side effects | sore throat, bleeding, dental injuries | 1h and 1 day after surgery |
Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Study Overview
=================
Brief Summary
-----------------
Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

Detailed Description
-----------------
Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Among commonly used CD63/CD203c markers, newly proposed molecules, such as CD69, CD107a, CD164, CD13, CD11b and CD300a will be assayed. Results obtained together with the other clinical data will be used to calculate sensitivity and specificity of the method.

Official Title
-----------------
Improved Basophil Activation Test (BAT) in the Diagnostics of IgE-mediated Drug Allergy

Conditions
-----------------
Drug Allergy, Antibiotic Allergy, NSAID-Induced Anaphylactoid Reaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected allergy to antibiotics or NSAIDs in the last 1 year. Exclusion Criteria: autoimmune diseases; HIV; hepatitis B/C; other acute or chronic infectious diseases; malignant neoplasms; leukemia; other severe acute or chronic intercurrent diseases; pregnancy/lactation; refuse of patient to participate in the trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with drug allergy<br>Patients with drug allergy to antibiotics or NSAIDs | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity of the improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy | Sensitivity of the improved Basophil Activation Test (BAT) in the diagnostics of allergy to antibiotics or NSAIDs | 1 month | 
| Specificity of the improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy | Specificity of the improved Basophil Activation Test (BAT) in the diagnostics of allergy to antibiotics or NSAIDs | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergy, Drug allergy, Basophil activation test, Flow cytometry
Efficacy of Transdermal Fentanyl for Chronic Neuropathic Pain

Study Overview
=================
Brief Summary
-----------------
The efficacy of fentanyl TTS for the treatment of neuropathic pain remains to be established, although opioids in general are clearly effective for neuropathic pain and fentanyl TTS has been shown to be effective for treating other types of pain. We propose to measure functional outcomes, pain relief and side effects of fentanyl TTS for the treatment of neuropathic pain. Measures will be made at baseline and after titrating the drug to an effective level.

Conditions
-----------------
Peripheral Neuropathy, Complex Regional Pain Syndromes (CRPS)

Intervention / Treatment
-----------------
* Drug: Transdermal Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years Neuropathic pain persisting for > 3 months Pain over the immediate previous three months The average of the least and usual pain intensity rating of 3 or greater (0-10 numerical rating scale) during the last week prior to enrollment Exclusion Criteria: A history of substance abuse Allergic reaction to an opioid Significant pain of alternate etiology other than the neuropathic pain state Severe pulmonary disease Recent myocardial infarction (within the preceding three months) Pregnancy Dementia Encephalopathy Those with life expectancy of less than six months and HIV seropositivity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Transdermal Fentanyl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain intensity (0-10) and daily activity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain relief (0-100%) |  |  | 
| Cognition (digital symbol and grooved peg-board) |  |  | 
| Impairment of function (MPI) and affect (BDI) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuropathic pain, Efficacy
Study Phase III Comparison of Superiority, Open With Blind Appraiser, to Evaluate the Efficacy and Safety of Barium Sulphate 66.7% With V (OPTI-BAR) Compared to Proceedings in Inert Radiological Examinations for the Diagnosis of Diseases for Image the Tratogastrointstinal

Study Overview
=================
Brief Summary
-----------------
Phase III clinical study, two samples, with assessor blind for the purpose of evaluating the efficacy and safety of the superiority of the use of barium sulphate 66.7% w/v (Opti-bar) as a contrast X-ray (X-ray).

Official Title
-----------------
STUDY PHASE III COMPARISON OF SUPERIORITY, OPEN WITH BLIND APPRAISER, TO EVALUATE THE EFFICACY AND SAFETY OF BARIUM SULPHATE 66.7% W / V (OPTI-BAR) COMPARED TO PROCEEDINGS IN INERT RADIOLOGICAL EXAMINATIONS FOR THE DIAGNOSIS OF DISEASES FOR IMAGE THE TRATOGASTROINTSTINAL.

Conditions
-----------------
X-ray Examinations of the Gastrointestinal Tract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women over 18 who need x-rays gastrointestinal tract with contrast; Healthy patient, ambulatory; Willingness to comply with the requirements of the study after signing an informed consent and (hit). Exclusion Criteria: Pregnant or lactating women; Patients allergic to barium sulfate, latex rubber or simethicone; Patients who have asthma, eczema, cystic fibrosis, heart disease, high blood pressure, rectal cancer, colostomy, obstruction in the stomach or intestines, pseudotumor cerebri, blocking stomach or intestinal disease, Hirsch or pseudotumor cerebri; Patients who have recently undergone a rectal biopsy or surgery or a recent history of drilling into your esophagus, stomach or intestines; Patients who have already participated in another clinical protocol in the last six months; Other clinical criteria that in the opinion of the study investigator could compromise the welfare of the patient or interfere with the results expected from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
SEBBIN INTEGRITY Round Implants

Study Overview
=================
Brief Summary
-----------------
This study is part of the clinical evaluation of SEBBIN silicone gel-filled INTEGRITY implants, included in the technical file of the device. The aim of the study is to gather additional data about the safety and effectiveness of the device.

Official Title
-----------------
Prospective Observational Study About SEBBIN Silicone Gel-filled INTEGRITY Mammary Implants

Conditions
-----------------
Complication, Prosthesis Durability

Intervention / Treatment
-----------------
* Device: Breast implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient is at least 18-year-old. The patient is a woman. The patient was prescribed with a surgery for a breast augmentation or reconstruction, unilaterally or bilaterally with silicone gel-filled SEBBIN INTEGRITY mammary implants. The patient has been informed of the study, has read the patient information letter and provided consent in writing. Exclusion Criteria: The patient is pregnant or breastfeeding. The patient has silicone implants somewhere else than in the breast. The patient was diagnosed with one of the following pathologies: Systemic lupus erythematous, Sjogren syndrome, scleroderma, polymyositis, or any other connective tissue disease. Rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, or any other inflammatory arthritic disease. Arthritis, fibromyalgia, chronic fatigue syndrome, or any other mechanic or degenerative non-inflammatory rheumatic disease. History of implant-associated anaplastic large cell lymphoma (BIA-ALCL). Symptomatic autoimmune disease. The patient has a pathology that could delay healing (does not apply to the reconstruction group). The patient has cancer (does not apply to the reconstruction group). The patient has anatomical or physiological conditions that could lead to postoperative complications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Breast implant|Patients operated for breast augmentation or reconstruction.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication rate |  | At 10 years of follow-up |
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Study Overview
=================
Brief Summary
-----------------
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Detailed Description
-----------------
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.

Official Title
-----------------
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Conditions
-----------------
Hormone Receptor Positive Malignant Neoplasm of Breast

Intervention / Treatment
-----------------
* Device: MammaPrint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30) ≥ 18 years of age at time of consent Written informed consent Exclusion Criteria: Insufficient tissue remaining for Mammaprint FFPE Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects with MammaPrint Result<br> | Device: MammaPrint<br>* All subjects<br>* Other names: 70 gene profile;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in recommended adjuvant chemotherapy treatment | The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result. A Chi-square test will be performed for the comparison of the two proportions. | 30 days |
Physicians International Coronary Computed Tomography Angiography (CCTA) Utilization Registry

Study Overview
=================
Brief Summary
-----------------
This protocol describes an observational study whose goal is to collect de-identified Coronary CT Angiography (CCTA) acquisition factors and interpretations (findings) from several hundred U.S. and international imaging facilities. The study uses an electronic data capture tool to collect de-identified CCTA utilization parameters and clinical findings in order to create a multi-center registry. This registry will be used for scientific analysis and publication of pertinent medical trends such as CT utilization, radiation dose, and common cardiovascular findings. The registry will be used to determine areas of interest for future randomized controlled trials. All data will be collected with patient identifiers removed and in complete accordance with HIPAA regulations. All data will be analyzed in aggregate, thus further minimizing the risk of patient confidentiality violations.

Official Title
-----------------
Physicians International CCTA Utilization Registry

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult participants who are able and willing to consent for themselves Patients scheduled for CCTA examination Exclusion Criteria: Patients who did not complete the planned CT imaging procedure due to mechanical error of the CT machine.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All comers >18 yrs old<br>This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CCTA utilization parameters and clinical findings |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 90 day MACE, Intended Care Management and Cost Effectiveness for cardiologists interpreting their CCTA studies |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (CHIP) in patients with a history of venous thromboembolism. The study investigators make the assumption that these patients present mutations involved in CHIP occurrence.

Official Title
-----------------
Screening of Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism

Conditions
-----------------
Venous Thromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women over 50 years old who have consulted at the Hematology laboratory of the Nîmes University Hospital for the occurrence or history of venous thromboembolism Patient who has accepted that their DNA was kept and used in the context of research on venous thromboembolism (biobank (registration number DC-2008-290 and authorization number AC-2008-107)) Exclusion Criteria: Patients less than 50 years old Patient who has refused that their DNA was kept and used in the context of research on venous thromboembolism

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Unprovoked proximal deep vein thrombosis<br> | |
| Provoked distal deep vein thrombosis<br> | |
| age-matched control group with no history of vein thrombosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DNMT3A mutations screening | Next generation sequencing | For sequencing analysis: 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TET2, ASXL1, TP53, JAK2, SF3B1, SRSF2, GNB1, CBL, BCOR, SH2B3, PPM1D mutations screening | Next generation sequencing | For sequencing analysis: 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clonal Hematopoiesis of indeterminate potential